Bottom line
MRAGX vs VONG: the short answer
MRAGX (Meridian Growth Fund) and VONG (Vanguard Russell 1000 Growth Index Fund) are both mutual funds.
But VONG is far broader, holding 396 positions to 91 for MRAGX, so beyond the top names it adds exposure MRAGX doesn't have.
VONG is cheaper at 0.06% vs 1.29% — a difference of $123 a year per $10,000 invested.
Over five years, VONG returned +18.9% a year vs −2.7% for MRAGX (reporting dates differ).
MRAGX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
MRAGX vs VONG side by side
| MRAGX | VONG | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Meridian | Vanguard |
| Category | Large Growth | Large Growth |
| Expense ratio | 1.29% | 0.06% |
| Annual cost per $10k | $129 | $6 |
| 10-yr cost on $10k (prospectus) | $2,042 | $77 |
| Max front load | 5.75% | None |
| 12b-1 fee | 0.25% | 0% |
| 1-yr return | −11.9% | +33.3% |
| 5-yr return (annualized) | −2.7% | +18.9% |
| 10-yr return (annualized) | +6.4% | +16.7% |
| Best quarter | — | +27.8% |
| Worst quarter | — | −20.9% |
| Net assets (fund) | $542.9M | $54.8B |
| Number of holdings | 91 | 396 |
| Portfolio turnover | 49% | 1% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
MRAGX and VONG share none of their top holdings.
MRAGX top 10
- Stit Govt And Agency Inst — 4.17%
- Rb Global Inc — 2.49%
- Curtiss-wright Corp — 2.46%
- Axogen Inc — 2.43%
- Federal Signal Corp — 2.36%
- Hinge Health Inc — 2.29%
- Definium Therapeutics Inc — 2.20%
- Veracyte Inc — 2.14%
- Standardaero Inc — 2.09%
- Turning Point Brands Inc — 2.08%
VONG top 10
- NVIDIA Corp — 13.07%
- Apple Inc — 11.95%
- Microsoft Corp — 8.96%
- Broadcom Inc — 5.77%
- Amazon.com Inc — 5.06%
- Alphabet Inc — 3.91%
- Tesla Inc — 3.48%
- Meta Platforms Inc — 3.19%
- Alphabet Inc — 3.15%
- Eli Lilly & Co — 2.67%
FAQ
What is the difference between MRAGX and VONG?
Which is cheaper, MRAGX or VONG?
Should I own both MRAGX and VONG?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.